Stock comparison
IDEXX Laboratories
Sanofi
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
SNY
Sanofi
Market cap
$106.67B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | SNY | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 61C | IDXX |
| Benjamin Graham | 80A | 40D | IDXX |
| Philip Fisher | 75B | 53C | IDXX |
| Peter Lynch | 71B | 39D | IDXX |
| Joel Greenblatt | 83C | 39D | IDXX |
| Charlie Munger | 87A | 48D | IDXX |
| Terry Smith | 84A | 49D | IDXX |
Side-by-side metrics
| Metric | IDXX | SNY |
|---|---|---|
| Market cap | $44.06B | $106.67B |
| P/E (TTM) | 39.0x | 8.6x |
| EV/EBIT | 31.6x | 10.8x |
| ROIC (TTM) | 40.66% | 11.66% |
| Gross margin | 62.05% | 71.62% |
| Net margin | 24.63% | 17.59% |
| Revenue CAGR 5y | 7.56% | 4.5% |
| EPS CAGR 5y | 10.79% | 6.47% |
| Debt / Equity | 0.7x | 0.3x |
| Dividend yield | 0.0% | 5.57% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 11.66%+71%
- Revenue CAGR 5y7.56%vs 4.5%+40%
- EPS CAGR 5y10.79%vs 6.47%+40%
- Net margin24.63%vs 17.59%+29%
SNY leads on
- Dividend yield5.57%vs 0.0%+100%
- P/E (TTM)8.6xvs 39.0x+78%
- EV/EBIT10.8xvs 31.6x+66%
- Debt / Equity0.3xvs 0.7x+60%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.